Amplifon
Market Cap
US$4.9b
Last Updated
2019/09/21 23:49 UTC
Data Sources
Company Financials +
Executive Summary
Amplifon SpA operates in the hearing care retail market that empowers people to rediscover various emotions of sound.
Snowflake
Fundamentals
Reasonable growth potential with imperfect balance sheet.
Share Price & News
How has Amplifon's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0%
AMFP.F
-0.04%
US Healthcare
-0.6%
US Market
1 Year Return
16.6%
AMFP.F
-9.1%
US Healthcare
0.7%
US Market
AMFP.F outperformed the Healthcare industry which returned -9.1% over the past year.
AMFP.F outperformed the Market in United States of America which returned 0.6% over the past year.
Share holder returns
| AMFP.F | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | -0.04% | -0.6% |
| 30 Day | n/a | 1.0% | 2.9% |
| 90 Day | n/a | -1.5% | 1.3% |
| 1 Year | 16.6%16.6% | -7.7%-9.1% | 2.9%0.7% |
| 3 Year | n/a | 29.6%24.3% | 44.6%35.2% |
| 5 Year | 363.9%363.9% | 66.1%56.2% | 61.9%44.2% |
Price Volatility Vs. Market
How volatile is Amplifon's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Amplifon undervalued based on future cash flows and its price relative to the stock market?
45.45x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
Amplifon's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
Amplifon's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
Amplifon is overvalued based on earnings compared to the US Healthcare industry average.
Amplifon is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Amplifon is poor value based on expected growth next year.
Price Based on Value of Assets
Amplifon is overvalued based on assets compared to the US Healthcare industry average.
Next Steps
Future Growth
How is Amplifon expected to perform in the next 1 to 3 years based on estimates from 10 analysts?
18.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Amplifon's revenue is expected to grow by 7.7% yearly, however this is not considered high growth (20% yearly).
Amplifon's earnings are expected to grow by 18.1% yearly, however this is not considered high growth (20% yearly).
Amplifon's revenue growth is expected to exceed the United States of America market average.
Amplifon's earnings growth is expected to exceed the United States of America market average.
Amplifon's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Amplifon is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
Next Steps
Past Performance
How has Amplifon performed over the past 5 years?
24.1%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Amplifon has delivered over 20% year on year earnings growth in the past 5 years.
Amplifon's 1-year earnings growth is negative, it can't be compared to the 5-year average.
Amplifon's 1-year earnings growth is negative, it can't be compared to the US Healthcare industry average.
Return on Equity
Amplifon has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
Amplifon used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.
Return on Capital Employed
Amplifon's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Amplifon's financial position?
Financial Position Analysis
Amplifon's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Amplifon's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Amplifon's level of debt (153.9%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has increased over the past 5 years (111.2% vs 153.9% today).
Debt is well covered by operating cash flow (25.2%, greater than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 16x coverage).
Balance Sheet
High level of physical assets or inventory.
Debt is not covered by short term assets, assets are 0.5x debt.
Next Steps
Dividend
What is Amplifon's current dividend yield, its reliability and sustainability?
0.89%
Expected Dividend Yield
Dividend Yield and Payments Analysis
Amplifon's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
Amplifon's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).
Amplifon is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
Amplifon is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to Shareholders
No need to calculate the sustainability of Amplifon's dividends as it is not paying a notable one for United States of America.
Future Payout to Shareholders
Dividends after 3 years are expected to be well covered by earnings (3.7x coverage).
Next Steps
Management
What is the CEO of Amplifon's salary, the management and board of directors tenure and is there insider trading?
2.8yrs
Average management tenure
CEO
Enrico Vita (50yo)
3.9yrs
Tenure
€2,918,000
Compensation
Mr. Enrico Vita has been Chief Executive Officer of Amplifon SpA since October 22, 2015 and Executive Director since October 20, 2015. Mr. Vita served as Chief Operating Officer and Executive Vice Presiden ...
CEO Compensation Analysis
Enrico's remuneration is lower than average for companies of similar size in United States of America.
Enrico's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.
Management Age and Tenure
2.8yrs
Average Tenure
43.5yo
Average Age
The tenure for the Amplifon management team is about average.
Board Age and Tenure
4.4yrs
Average Tenure
57yo
Average Age
The tenure for the Amplifon board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Enrico Vita (50yo)
CEO & Executive Director
- Tenure: 3.9yrs
- Compensation: €2.92m
Paolo Tacciaria
Head of Internal Audit
- Tenure: 0yrs
Gabriele Galli (50yo)
Chief Financial Officer
- Tenure: 2.5yrs
Giulio Pizzini (45yo)
Chief Strategic Development Officer
- Tenure: 4yrs
Francesca Rambaudi
Investor Relations & Corporate Communication Director
- Tenure: 3.8yrs
Cristian Finotti (50yo)
Chief Supply Chain Officer
- Tenure: 3.5yrs
Francesca Morichini (41yo)
Chief HR Officer
- Tenure: 1.9yrs
Alessandro Bonacina (41yo)
Chief Marketing Officer
- Tenure: 2.6yrs
Gabriele Chiesa (42yo)
Chief Information Officer
- Tenure: 1.5yrs
Federico Poz (41yo)
Chief Legal Officer
- Tenure: 2.8yrs
Board Members
Andrea Casalini (57yo)
Independent Director
- Tenure: 3.4yrs
- Compensation: €85.00k
Giovanni Tamburi (65yo)
Director
- Tenure: 6.4yrs
- Compensation: €55.00k
Susan Holland (63yo)
Chairperson
- Tenure: 8.4yrs
- Compensation: €304.00k
Maurizio Costa (71yo)
Independent Director
- Tenure: 12.3yrs
- Compensation: €85.00k
Enrico Vita (50yo)
CEO & Executive Director
- Tenure: 3.9yrs
- Compensation: €2.92m
Maria Patrizia Grieco (67yo)
Independent Director
- Tenure: 0yrs
- Compensation: €75.00k
Lorenzo Pozza (53yo)
Lead Independent Director
- Tenure: 0yrs
- Compensation: €100.00k
Alessandro Cortesi (57yo)
Independent Director
- Tenure: 3.4yrs
- Compensation: €80.00k
Raffaele Pagani
Chairperson of the Board of Statutory Auditors
- Tenure: 4.4yrs
Laura Donnini (56yo)
Independent Director
- Tenure: 0yrs
- Compensation: €90.00k
Company Information
Amplifon SpA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Amplifon SpA
- Ticker: AMFP.F
- Exchange: OTCPK
- Founded: 1950
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: €4.941b
- Listing Market Cap: €5.436b
- Shares outstanding: 222.37m
- Website: https://corporate.amplifon.com
Number of Employees
Location
- Amplifon SpA
- Via Ripamonti No. 133
- Milan
- Milan
- 20141
- Italy
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AMFP.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jun 2001 |
| AMP | BIT (Borsa Italiana) | Yes | Ordinary Shares | IT | EUR | Jun 2001 |
| 0N61 | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jun 2001 |
| AXNA | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jun 2001 |
| AMPM | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jun 2001 |
Biography
Amplifon SpA operates in the hearing care retail market that empowers people to rediscover various emotions of sound. The company operates through a network of approximately 11,000 points of sale in 29 cou ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/21 23:49 |
| End of Day Share Price | 2019/09/06 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.